A pathophysiology diagram illustrating the mechanism of immune checkpoint inhibitors (ICIs) in cancer immunotherapy, specifically focusing on the PD1/PD-L1 pathway. The diagram is split into two comparative scenarios. The top section depicts the 'Absence of immune-checkpoint inhibitors,' where a T-cell's PD1 receptor binds to a cancer cell's PD-L1 receptor. Despite TCR-MHC engagement, this inhibitory binding leads to T-cell exhaustion and cancer cell survival. The bottom section depicts the 'Presence of immune-checkpoint inhibitors,' where anti-PD1 or anti-PD-L1 antibodies (ICIs) block the PD1/PD-L1 interaction (represented by a red 'no' symbol). This blockade results in T-cell activation, evidenced by the release of effector molecules like Perforin (PFN), Granzyme (Gzm), Interferon-gamma (IFNy), and Tumor Necrosis Factor-alpha (TNFa). The consequence is visualized as 'Cancer cell death,' shown by the fragmentation and lysis of the cancer cell. The diagram serves as an educational tool for oncology and immunology, explaining how checkpoint blockade restores the cytotoxic antitumor response.

A pathophysiology diagram illustrating the mechanism of immune checkpoint inhibitors (ICI) in cancer immunotherapy. The illustration is divided into two main panels comparing 'Non-ICI' and 'ICI therapy' conditions. The left panel depicts interactions between a cancer cell and a T-cell; in the 'Non-ICI' state, PD-L1/PD-L2 on the cancer cell binds to PD-1 on the T-cell, leading to T-cell inactivation and tumor evasion. Under 'ICI therapy,' antibodies (anti-PD-1, anti-PD-L1, anti-PD-L2) block these inhibitory receptors, resulting in an active T-cell and tumor eradication. The right panel shows the interaction between an antigen-presenting cell (APC) and a T-cell. In the 'Non-ICI' state, CD80/86 on the APC binds to CTLA-4 on the T-cell, causing inactivation and tumor evasion. Under 'ICI therapy,' anti-CTLA-4 antibodies block this pathway, facilitating T-cell activation and tumor eradication. Both panels include common MHC-TCR complex signaling. This educational graphic demonstrates how monoclonal antibodies restore the anti-tumor immune response by preventing inhibitory checkpoint signaling.

This medical illustration depicts two major immune checkpoint pathways, PD-1/PD-L1 and CTLA-4, in the context of cancer immunology and immunotherapy. Section A illustrates the PD-1/PD-L1 pathway, showing a tumor-burdened liver associated with the expression of PD-1 in various immune cells including T cells, B cells, NK cells, MDSC, and DCs. This signaling involves the tyrosine phosphatase SHP-2, leading to the inhibition of the immune system and prevention of autoimmunity. Simultaneously, PD-L1 expression on somatic cells is shown to suppress T-cell migration, proliferation, and the release of cytotoxic cytokines. Section B details the CTLA-4 pathway, demonstrating how CTLA-4 expression on T cells interacts with Antigen-Presenting Cells (APCs), resulting in decreased IL-2 levels and subsequent inhibition of T-cell proliferation. It also shows the role of CTLA-4 in stimulating TGF-β, which influences Regulatory T cells (Tregs). The diagram highlights the clinical application of Anti-PD-1/PD-L1 and Anti-CTLA-4 therapies (Immune Checkpoint Inhibitors) in enhancing effector T-cell function (T(eff)) for treating malignancies such as hepatocellular carcinoma (HCC).

This medical pathophysiology diagram illustrates the role of PD-L1 expression in cancer immunotherapy, specifically comparing a PD-L1 positive tumor microenvironment (TME) with systemic PD-L1 expression in patients with PD-L1 negative tumors. The left panel shows a PD-L1 positive tumor where tumor cells and antigen-presenting cells (APCs) utilize the PD-L1/PD-1 pathway to inhibit CD8+ T cells. Therapeutic anti-PD1/PD-L1 antibodies are depicted blocking these interactions to restore immune response. The right panel illustrates the concept of 'Systemic Immunity' in a PD-L1 negative tumor context, featuring a human silhouette with an enlarged view of peripheral blood. This section identifies systemic PD-L1 positive populations that may influence clinical responses even when the primary tumor is PD-L1 negative. These populations include soluble PD-L1 (sPD-L1), myeloid-derived suppressor cells (MDSCs), circulating tumor cells (CTCs), monocytes, neutrophils, and dendritic cells (DCs). This diagram highlights the significance of the myeloid compartment and circulating biomarkers in patient stratification for immune checkpoint inhibitor (ICI) therapy in oncology.